{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"With Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Without Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Response to therapy is defined as survival to Day 28 of study, PLUS complete discontinuation all supplemental oxygen support by Day 28 of study. Subjects must be able to remain off all supplemental oxygen support for \\> 72 consecutive hours. Subjects who discontinue supplemental oxygen within the last 72 hours of the observation period will be followed until they have completed 72 consecutive hours off oxygen or failed prior to assessing response.","groups":[{"description":"Patients receive etanercept IV (dose 0.4 mg/kg- max 25 mg) over 30 minutes on day 0 and subcutaneously (dose 0.4 mg/kg- max 25 mg) on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV (dose 2.0 mg/kg/day) on days 0-2 and then orally with a taper beginning day 7. Dose on days 7-20 (1.0 mg/kg/day), days 21-34 (0.5 mg/kg/day), days 35-48 (0.25 mg/kg/day) and days 49-56 (0.25 mg/kg/every other day) discontinuing on day 56.\n\netanercept: Given IV and subcutaneously\n\nmethylprednisolone: Given IV and orally","id":"OG000","title":"Etanercept and Corticosteroid Therapy"}],"paramType":"NUMBER","populationDescription":"Analysis population includes all patients who are eligible and had sufficient data to evaluate response. Eleven ineligible patients are excluded.","reportingStatus":"POSTED","timeFrame":"At day 28","title":"Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28.","type":"PRIMARY","unitOfMeasure":"participants"}